{
  "SAA": "severe aplastic anemia",
  "ELT": "eltrombopag",
  "PNH": "paroxysmal nocturnal hemoglobinuria",
  "GVHD": "graft versus host disease",
  "OS": "overall survival",
  "BCVA": "best corrected visual acuity",
  "ICBD": "international criteria behçet disease",
  "KS": "kaposi sarcoma",
  "BORR": "best overall response rate",
  "ANC": "absolute neutrophil count",
  "ORR": "overall response rate",
  "HIV": "human immunodeficiency virus",
  "CNS": "central nervous system",
  "BBB": "blood brain barrier",
  "US": "ultrasound",
  "MSD": "most successful dose",
  "PS": "performance status",
  "SOC": "standard of care",
  "IDA": "idarubicin",
  "ED": "early date",
  "DLTS": "dose limiting toxicities",
  "MTD": "maximal tolerated dose",
  "SSZ": "sulfasalazine",
  "DLT": "dose limiting toxicity",
  "PK": "pharmacokinetics",
  "PD": "pharmacodynamics",
  "EOI": "end of induction",
  "SAES": "serious adverse events",
  "DSMB": "data safety monitoring board",
  "ULN": "upper limit normal",
  "DL": "dose levels",
  "CRM": "continual reassessment method",
  "PRCA": "pure red cell aplasia",
  "AA": "aplastic anemia",
  "EPAG": "eltrombopag",
  "AIEC": "adherent invasive e coli",
  "TA": "takayasu arteritis",
  "CS": "corticosteroids",
  "ACR": "american college rheumatology",
  "ALAT": "alanine-aminotransferase it: intra-thecal",
  "ASAT": "aspartate amino transferase lr: low risk",
  "AT": "anti thrombin lwh: low weight heparin",
  "BID": "twice a day mmolr: major molecular response",
  "BM": "bone marrow mrd: minimal residual disease",
  "CIR": "cumulative incidence relapse",
  "CIV": "continuousintravenous nrm: non relapse related mortality",
  "CML": "chronicmyelogenous leukemia nyha: “new york heart association”",
  "CPM": "cyclophosphamide pb: peripheral bloodphrc: “programme hospitalier",
  "CSF": "cerebro spinal fluid rbc: red blood cells",
  "DIVC": "disseminated intravascular coagulation rtc: reduced toxicity conditioning",
  "DMA": "drug marketing authorization sae: serious adverse event",
  "DVI": "dexamethasone, vincristine, itk sgot: serum glutamic oxaloacetictransferase",
  "ECG": "electrocardiogram sgpt: serum glutamopyruvatetransferase",
  "FFD": "form of functions delegation spc: summary of product characteristics",
  "FFP": "fresh frozen plasma sr: standard risk",
  "FGM": "france greffe de moelle tbi: total body irradiation",
  "FR": "shortening fraction td: total dose",
  "G-CSF": "granulocyte colony-stimulating factor tki: tyrosine kinase inhibitor",
  "GNB": "gram negative bacteria tlp: traumatic lumbar puncture",
  "GPB": "gram positive bacteria tua: temporary usage authorization",
  "GVH": "graft versus host uln: upper limit of normal",
  "HCR": "hematologic complete remission vcr: vincristine",
  "HD": "high dose vds: vindesine",
  "HLA": "human leukocyte antigen vef: ventricular ejection fraction",
  "HSC": "hematopoietic stem cells vp-16: etoposide",
  "GRAALL-2014": "–summary 4/178",
  "SR": "standard risk",
  "NRM": "non relapse mortality",
  "AR": "adverse reaction",
  "ASR": "annual safety report",
  "CA": "competent authority",
  "CBC": "complete blood count",
  "CDED": "crohn disease exclusion diet",
  "CDAI": "crohn’s disease activity index",
  "CDEIS": "crohn’s disease endoscopic index of severity",
  "CV": "curriculum vitae",
  "EEN": "exclusive enteral nutrition",
  "FCP": "faecal calprotectin",
  "HBI": "harvey-bradshaw index",
  "IBD": "inflammatory bowel disease",
  "IBDQ": "inflammatory bowel disease questionnaire",
  "ICF": "informed consent form",
  "PCC": "pillcam crohn capsule",
  "PEN": "partial enteral nutrition",
  "PIL": "patient information letter",
  "SAP": "statistical analysis plan",
  "SES-CD": "simple endoscopic score for crohn’s disease",
  "SF16": "short form 16",
  "SUSAR": "suspected unexpected serious adverse reaction",
  "WPAI": "work productivity index",
  "RIC": "reduced intensity conditioning",
  "GVL": "graft versus leukemia",
  "GRFS": "gvhd relapse free survival",
  "WCBP": "women child bearing potential",
  "AHSCT": "autologous hematopoietic stem cell transplantation",
  "CTC-AE": "nci common terminology criteria for adverse events",
  "CRISS": "acr provisional composite response index for clinical trials in early diffuse",
  "DLCO": "diffusing capacity of lung for carbon monoxide",
  "EQ-5D-5L": "euroqol 5-dimension 5-level",
  "FVC": "forced vital capacity",
  "GMP": "good manufacturing practices",
  "GRCS": "global rank composite score",
  "MMF": "mycophenolate mofetil",
  "QALY": "quality-adjusted life year",
  "SAR": "serious adverse reactions",
  "SHAQ": "scleroderma-health assessment questionnaire",
  "SF-36": "the short form (36) health survey",
  "TRSAE": "treatment related severe adverse events",
  "SCT": "stem cell transplantation",
  "ASCT": "autologous stem cell transplantation",
  "CCTAE": "common toxicity criteria",
  "DOR": "duration of response",
  "EOT": "end of treatment",
  "GI": "gastro intestinal",
  "IMWG": "international myeloma working group",
  "ISS": "international staging system",
  "VRD": "bortezomib-lenalidomide-dexamethasone",
  "MHSC": "mobilization and harvesting stem cells",
  "MM": "multiple myeloma",
  "NCI": "national cancer institute",
  "NGS": "next-generation sequencing",
  "PCL": "primitive plasma cell leukemia",
  "SC": "subcutaneous",
  "SPM": "second primary malignancy",
  "TTP": "time to progression",
  "VGPR": "very good partial response",
  "PPCL": "primary plasma cell leukemia",
  "PCR": "polymerase chain reaction",
  "HBV": "hepatitis b virus",
  "KTR": "kidney transplant recipients",
  "UTI": "urinary tract infection",
  "MDR": "multidrug",
  "QOL": "quality of life",
  "CI": "confidence intervals",
  "FFS": "failure free survival",
  "ACE2": "angiotensin converting enzyme 2",
  "BUN": "blood urea nitrogen",
  "CNIL": "commission nationale informatique et libertés",
  "COPD": "chronic obstructive pulmonary disease",
  "CPK": "creatinine phosphokinase",
  "CRB": "centre de ressources biologiques",
  "CRPV": "centre régional de pharmacovigilance",
  "DSUR": "development safety update report",
  "ECMO": "extra corporeal membrane oxygenation",
  "EMA": "european medicine agency",
  "ER": "emergency room",
  "GP": "general practitioner",
  "HCSP": "haut conseil à la santé publique",
  "ICU": "intensive care unit",
  "IEAC": "independent endpoint adjudication comittee",
  "NIV": "non invasive ventilation",
  "PHRC": "programme hospitalier de recherche clinique",
  "PI": "principal investigator",
  "RTPCR": "reverse transcription polymerase chain reaction",
  "RRT": "renal replacement therapy",
  "SBIM": "service de biostatistique et information médicale",
  "TMPRSS2": "cellular serine protease",
  "WHO": "world health organization",
  "AES": "adverse events",
  "GPS": "general practitioners",
  "GHSIF": "groupe hospitalier sud ile france",
  "ADCC": "antibody dependent cell-mediated cytotoxicity",
  "ATC": "anatomical-therapeutic-chemical classification",
  "AUC": "area under the curve",
  "AZA": "azathioprine",
  "BRB": "blood-retinal barrier",
  "CHO": "chinese hamster ovary",
  "CINCA": "chronic infantile neurological cutaneous articular",
  "CSA": "cyclosporine a",
  "EAU": "experimental autoimmune uveitis/uveoretinitis",
  "CME": "cystoid macular edema",
  "MAMS": "multi arm multi stage",
  "MC": "mixed cryoglobulinaemia",
  "MGUS": "monoclonal gammapathy unknown significance",
  "BVAS": "birmingham vasculitis activity score",
  "MCC": "merkel cell carcinoma",
  "DME": "drug metabolizing enzymes",
  "MAR": "missing at random",
  "ODV": "odemethylv",
  "SLE": "systemic lupus erythematosus",
  "MCR": "major clinical response",
  "SCD": "sickle cell disease",
  "TBI": "total body irradiation",
  "CT": "computed tomography",
  "NYHA": "new york heart association",
  "ADR": "adverse drug reaction",
  "CMU": "couverture maladie universelle",
  "DSMC": "data safety monitoring committee",
  "EDC": "electronic data capture",
  "ELISA": "enzyme linked immunosorbent assay",
  "IPDMA": "individual patient data meta-analysis",
  "IRB": "institutional review board",
  "MDW": "monocyte distribution width",
  "DUSP-1": "dual-specificity phosphatase 1",
  "RCT": "randomized controlled trial",
  "REB": "research ethics board",
  "SADR": "serious adverse drug reaction",
  "SOFA": "score sequential organ failure assessment score",
  "SUADR": "serious unexpected adverse drug reaction",
  "URC": "hupifo paris ile de france ouest clinical research unit",
  "API": "active pharmaceutical ingredient",
  "CMO": "contract manufacturing organization",
  "DEX": "dexamethasone",
  "EIG": "événement indésirable grave (voir sae)",
  "HD-MTX": "high-dose methotrexate",
  "IM": "intramuscular",
  "IMP": "investigational medicinal product",
  "IT": "intrathecal injection",
  "MR": "medium risk",
  "MTX": "methotrexate",
  "NCI-CTCAE": "national cancer institute common terminology criteria for adverse events",
  "PEG": "pegaspargase",
  "PNN": "neutrophils",
  "PRED": "prednisone",
  "TLP": "traumatic lumbar puncture",
  "VCR": "vincristine",
  "VHR": "very high risk",
  "ASNASE": "asparaginase",
  "DI": "delayed intensifications",
  "GPR": "good prednisone response",
  "PPR": "poor prednisone response",
  "HS": "hemophagocytic syndrome",
  "ARF": "acute respiratory failure",
  "DNI": "do not intubate",
  "BD": "behçet disease",
  "DSA": "donor specific antibody",
  "EVT": "endovascular therapy",
  "IVT": "intravenous thrombolysis",
  "MCA": "middle cerebral artery",
  "MT": "mechanical thrombectomy",
  "MRI": "magnetic resonance imaging",
  "MRA": "magnetic resonance angiography",
  "AIS": "acute ischemic stroke",
  "LVO": "large vessel occlusion",
  "ICA": "internal carotid artery",
  "CTP": "perfusion ct-scan",
  "DAPT": "dual anti platelet therapy",
  "BRE": "bleeding-related event",
  "SUSARS": "suspected unexpected serious adverse reactions",
  "BRES": "bleeding related events"
}